ADC Drug Development
Comprehensive consulting for Antibody-Drug Conjugate development from target selection through clinical development and regulatory approval.
Key Capabilities
- Target antigen selection and validation for ADC programs
- Antibody engineering and optimization strategies
- Linker-payload selection and conjugation chemistry
- Preclinical efficacy and safety assessment
- CMC development for ADC manufacturing
- IND-enabling studies and regulatory strategy
- Clinical development planning and protocol design
Our Approach
Antibody-Drug Conjugates represent one of the most promising modalities in oncology. Bionavigen brings deep expertise in all aspects of ADC development, from early target identification through late-stage clinical development.
Our team has hands-on experience with multiple ADC programs, providing guidance on the critical decisions that determine ADC success: target selection, antibody format, linker chemistry, payload selection, and conjugation strategy.
We support clients in navigating the complex regulatory landscape for ADCs, leveraging our experience with FDA interactions and BLA submissions to accelerate development timelines.